Hepatic expression of GAA results in enhanced enzyme bioavailability in mice and non-human primates - Sorbonne Université
Article Dans Une Revue Nature Communications Année : 2021

Hepatic expression of GAA results in enhanced enzyme bioavailability in mice and non-human primates

Natalie Daniele
  • Fonction : Auteur
Bernard Gjata
  • Fonction : Auteur
Jeremie Cosette
  • Fonction : Auteur

Résumé

Pompe disease (PD) is a severe neuromuscular disorder caused by deficiency of the lysosomal enzyme acid alpha-glucosidase (GAA). PD is currently treated with enzyme replacement therapy (ERT) with intravenous infusions of recombinant human GAA (rhGAA). Although the introduction of ERT represents a breakthrough in the management of PD, the approach suffers from several shortcomings. Here, we developed a mouse model of PD to compare the efficacy of hepatic gene transfer with adeno-associated virus (AAV) vectors expressing secretable GAA with long-term ERT. Liver expression of GAA results in enhanced pharmacokinetics and uptake of the enzyme in peripheral tissues compared to ERT. Combination of gene transfer with pharmacological chaperones boosts GAA bioavailability, resulting in improved rescue of the PD phenotype. Scale-up of hepatic gene transfer to non-human primates also successfully results in enzyme secretion in blood and uptake in key target tissues, supporting the ongoing clinical translation of the approach.
Fichier principal
Vignette du fichier
s41467-021-26744-4.pdf (4.05 Mo) Télécharger le fichier
Origine Publication financée par une institution

Dates et versions

hal-03449262 , version 1 (25-11-2021)

Licence

Identifiants

Citer

Helena Costa-Verdera, Fanny Collaud, Christopher R Riling, Pauline Sellier, Jayme M L Nordin, et al.. Hepatic expression of GAA results in enhanced enzyme bioavailability in mice and non-human primates. Nature Communications, 2021, 12 (1), pp.6393. ⟨10.1038/s41467-021-26744-4⟩. ⟨hal-03449262⟩
82 Consultations
48 Téléchargements

Altmetric

Partager

More